Radius Health, Inc. RDUS
We take great care to ensure that the data presented and summarized in this overview for Radius Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RDUS
Top Purchases
Top Sells
About RDUS
Insider Transactions at RDUS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2022
|
Machelle Sanders Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,500
-100.0%
|
$55,000
$10.0 P/Share
|
|
Aug 15
2022
|
Chhaya Shah Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
94,645
-100.0%
|
$946,450
$10.0 P/Share
|
|
Aug 15
2022
|
Andrew C. Von Eschenbach Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,500
-100.0%
|
$55,000
$10.0 P/Share
|
|
Aug 15
2022
|
Sean Murphy Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,500
-100.0%
|
$55,000
$10.0 P/Share
|
|
Aug 15
2022
|
Elizabeth Messersmith Senior Vice President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
70,000
-100.0%
|
$700,000
$10.0 P/Share
|
|
Aug 15
2022
|
G. Kelly Martin CEO and President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
75,000
-100.0%
|
$750,000
$10.0 P/Share
|
|
Aug 15
2022
|
Owen Hughes Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
21,650
-100.0%
|
$216,500
$10.0 P/Share
|
|
Aug 15
2022
|
Danielle Holtschlag Vice President, Sales |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,000
-100.0%
|
$250,000
$10.0 P/Share
|
|
Aug 15
2022
|
Jean Pierre Garnier Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,500
-100.0%
|
$55,000
$10.0 P/Share
|
|
Aug 15
2022
|
Jean Pierre Garnier Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
26,800
-82.97%
|
$268,000
$10.0 P/Share
|
|
Aug 15
2022
|
Cathy Friedman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
26,800
-100.0%
|
$268,000
$10.0 P/Share
|
|
Aug 15
2022
|
Willard H Dere Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,895
-100.0%
|
$18,950
$10.0 P/Share
|
|
Aug 15
2022
|
Willard H Dere Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
21,300
-91.83%
|
$213,000
$10.0 P/Share
|
|
Aug 11
2022
|
Target N V Biotech > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,733,538
-100.0%
|
$87,335,380
$10.0 P/Share
|
|
Aug 11
2022
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,678,954
+16.27%
|
$16,789,540
$10.07 P/Share
|
|
Aug 10
2022
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,012
+0.06%
|
$40,120
$10.07 P/Share
|
|
May 18
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
477,824
+5.19%
|
$2,389,120
$5.57 P/Share
|
|
Mar 15
2022
|
Mark William Conley VP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Feb 21
2022
|
G. Kelly Martin CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
1,035,000
+50.0%
|
-
|
|
Jan 14
2022
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+19.17%
|
-
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders